Sitryx initiates Phase 1 clinical trial of potential disease-modifying treatment for atopic dermatitis SYX-5219 SYX-5219 is a ...

Previously reported Phase 1/2 data on WU-CART-007 demonstrated clinically manageable safety and evidence of anti-leukemic activity with an overall response rate of 91% and composite complete remission ...

Century Therapeutics has joined the onslaught of cell therapy biotechs taking hits, discontinuing a phase 1 cancer study to ...

The Data Safety Monitoring Board (DSMB) identified no safety concerns, and recommended continuation of BriaCell's pivotal Phase 3 study of Bria-IMT™ plus immune check point inhibitor in metastatic ...

Stomach cancer, also known as gastric cancer, is the fifth most common cancer worldwide, with nearly one million new cases in ...

City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States and a ...

We have two types of hair, says dermatologist Elizabeth Houshmand. Vellus hairs, or “peach fuzz,” cover virtually our entire ...

As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer ...

In an early-stage clinical trial, the therapy nearly doubled the expected survival time of young patients. Still, experts ...

Scientists have carefully examined somatic mutations in stomach lining tissue to uncover mutational mechanisms that can lead ...

Golidocitinib is a JAK1 only inhibitor approved for the treatment of relapsed or refractory PTCL The combination of ...

A vaccine's ability to generate long-lasting, high-affinity antibodies hinges on a delicate balance. Upon exposure to a ...